Have Insiders Sold Meihao Medical Group Shares Recently?
Have Insiders Sold Meihao Medical Group Shares Recently?
We wouldn't blame Meihao Medical Group Co., Ltd (HKG:1947) shareholders if they were a little worried about the fact that Xiaomin Wang, the Co-Founder recently netted about HK$15m selling shares at an average price of HK$0.27. That's a big disposal, and it decreased their holding size by 14%, which is notable but not too bad.
如果美好医疗集团有限公司(HKG:1947)的股东对其共同创始人王小敏最近以平均价格HK$0.27出售约HK$1500万的股票感到有些担忧,我们并不会责怪他们。这是一笔大交易,减少了他们的持股比例14%,虽然显著但也不是太糟。
Meihao Medical Group Insider Transactions Over The Last Year
美好医疗集团内部交易过去一年
Notably, that recent sale by Xiaomin Wang is the biggest insider sale of Meihao Medical Group shares that we've seen in the last year. So it's clear an insider wanted to take some cash off the table, even below the current price of HK$0.36. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. This single sale was just 14% of Xiaomin Wang's stake.
值得注意的是,王小敏最近的出售是我们在过去一年中看到的美好医疗集团股票最大的一笔内部出售。因此,很明显一位内部人士想要套现,即使低于当前HK$0.36的价格。当内部人士在当前价格以下出售时,表明他们认为那个较低的价格是合理的。这让我们想知道他们对(较高的)最近估值的看法。然而,尽管内部出售有时令人沮丧,但它只是一个微弱的信号。这一笔出售仅占王小敏持股的14%。
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
SEHK:1600内部交易成交量:2024年6月5日
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20241121/0-0ca5beccc39fd258207764622831a45c-0-999fb37a95c007099cdad067faa87fd4.png/big)
I will like Meihao Medical Group better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我看到一些大规模的内幕买入,我会更喜欢美好医疗集团。在我们等待的同时,查看这个免费的被低估和小盘股票列表,这些股票最近有大量的内幕买入。
Insider Ownership
内部人员持股情况
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Meihao Medical Group insiders own 71% of the company, currently worth about HK$156m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
我喜欢查看公司内部人士持有多少股票,以此来帮助我判断他们与内部人士的利益一致程度。通常,内部人士的持股比例越高,内部人士越可能受到激励,以长期发展公司。美好医疗集团的内部人士目前持有公司71%的股份,基于最近的股价,价值约为15600万港元。大多数股东会乐于看到这种内幕持股,因为这表明管理层的激励与其他股东的利益保持一致。
So What Do The Meihao Medical Group Insider Transactions Indicate?
那么,美好医疗集团的内幕交易表明了什么?
An insider sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 3 warning signs for Meihao Medical Group you should be aware of, and 1 of these is concerning.
一位内部人士最近出售了股票,但他们没有进行买入。即使我们回顾过去一年,也没有看到任何购买。这家公司拥有较高的内部持股,但考虑到历史上的股票出售,我们有些犹豫。虽然了解内部人士的持股和交易动态是有好处的,但在做出任何投资决策之前,我们也要考虑股票面临的风险。举个例子:我们发现美好医疗集团有3个值得注意的警示信号,其中1个引起了我们的关注。
Of course Meihao Medical Group may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然,美好医疗集团可能不是最佳的买入股票。因此,您可能希望查看这份优质公司免费集合。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。